Status:

COMPLETED

Complement Activation During Hemodialysis in Atypical Hemolytic Uraemic Syndrome as Underlying Kidney Disease

Lead Sponsor:

University Hospital, Ghent

Conditions:

Atypical Hemolytic Uraemic Syndrome

Eligibility:

All Genders

18+ years

Brief Summary

Atypical hemolytic uraemic syndrome is caused by defects in the regulating factors in the alternative pathway of the complement system. Triggering can cause an uncontrolled complement activation with ...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • cases: endstage renal failure due to atypical hemolytic uraemic syndrome treated with hemodialysis.
  • controls: endstage renal failure due to a non complement consuming nephropathy treated with hemodialysis.

Exclusion

    Key Trial Info

    Start Date :

    August 1 2009

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    July 1 2015

    Estimated Enrollment :

    25 Patients enrolled

    Trial Details

    Trial ID

    NCT00930423

    Start Date

    August 1 2009

    End Date

    July 1 2015

    Last Update

    December 15 2022

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    University Hospital Ghent

    Ghent, Belgium, 9000